Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Clinicopathological and Prognostic Significance of HER2-Low Breast Cancer: A Comparative Analysis Between HER2-Low and HER2-Zero Subtypes.
Nishimura R, Fujiki Y, Taira T, Miyaki T, Kanemitsu S, Yotsumoto D, Teraoka M, Kawano J, Gondo N, Mitsueda R, Baba S, Ohi Y, Rai Y, Sagara Y, Sagara Y. Nishimura R, et al. Among authors: miyaki t. Clin Breast Cancer. 2024 Feb 22:S1526-8209(24)00051-X. doi: 10.1016/j.clbc.2024.02.013. Online ahead of print. Clin Breast Cancer. 2024. PMID: 38472058
Prognostic nutritional index after introduction of atezolizumab with bevacizumab predicts prognosis in advanced hepatocellular carcinoma: A multicenter study.
Suzuki T, Matsuura K, Suzuki Y, Okumura F, Nagura Y, Sobue S, Kato D, Kusakabe A, Koguchi H, Hasegawa I, Matoya S, Miyaki T, Kimura Y, Tanaka Y, Kondo H, Ozasa A, Kawamura H, Kuno K, Fujiwara K, Nojiri S, Kataoka H; Sakurayama Liver Study Group. Suzuki T, et al. Among authors: miyaki t. Oncology. 2024 Jan 18. doi: 10.1159/000536367. Online ahead of print. Oncology. 2024. PMID: 38237558
Serum CXCL10 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced BCLC stage C hepatocellular carcinoma: A multicenter analysis.
Suzuki T, Matsuura K, Suzuki Y, Okumura F, Nagura Y, Sobue S, Matoya S, Miyaki T, Kimura Y, Kusakabe A, Narahara S, Tokunaga T, Nagaoka K, Kuroyanagi K, Kawamura H, Kuno K, Fujiwara K, Nojiri S, Kataoka H, Tanaka Y. Suzuki T, et al. Among authors: miyaki t. Cancer Med. 2023 Dec 22;13(1):e6876. doi: 10.1002/cam4.6876. Online ahead of print. Cancer Med. 2023. PMID: 38133557 Free PMC article.
Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus.
Tahata Y, Hikita H, Mochida S, Enomoto N, Ido A, Kuroda H, Miki D, Kurosaki M, Hiasa Y, Sakamori R, Kawada N, Yamashita T, Suda G, Yatsuhashi H, Yoshiji H, Kato N, Takami T, Nakao K, Matsuura K, Asahina Y, Itoh Y, Tateishi R, Nakamoto Y, Kakazu E, Terai S, Shimizu M, Ueno Y, Akuta N, Miyazaki M, Nozaki Y, Kabayama M, Sobue S, Moriuchi A, Miyaki T, Kodama T, Tatsumi T, Yamada T, Takehara T. Tahata Y, et al. Among authors: miyaki t. J Gastroenterol. 2023 Dec;58(12):1211-1221. doi: 10.1007/s00535-023-02039-x. Epub 2023 Oct 13. J Gastroenterol. 2023. PMID: 37831182 Free PMC article.
Lung fusion with the liver in chick and quail embryos.
Kim JH, Hayashi S, Murakami G, Rodríguez-Vázquez JF, Miyaki T. Kim JH, et al. Among authors: miyaki t. Anat Histol Embryol. 2023 Jul;52(4):552-559. doi: 10.1111/ahe.12913. Epub 2023 Mar 7. Anat Histol Embryol. 2023. PMID: 36881478
The neutrophil-to-lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis.
Matoya S, Suzuki T, Matsuura K, Suzuki Y, Okumura F, Nagura Y, Sobue S, Kuroyanagi K, Kusakabe A, Koguchi H, Hasegawa I, Miyaki T, Tanaka Y, Kondo H, Kimura Y, Ozasa A, Kawamura H, Kuno K, Fujiwara K, Nojiri S, Kataoka H; Sakurayama Liver Study Group (SLSG). Matoya S, et al. Among authors: miyaki t. Hepatol Res. 2023 Jun;53(6):511-521. doi: 10.1111/hepr.13886. Epub 2023 Feb 18. Hepatol Res. 2023. PMID: 36723964
Outcome of nucleos(t)ide analog cessation in patients with treatment for prevention of or against hepatitis B virus reactivation.
Suzuki T, Matsuura K, Urakabe K, Okumura F, Kawamura H, Sobue S, Matoya S, Miyaki T, Kimura Y, Kato D, Kusakabe A, Tanaka Y, Ozasa A, Nagura Y, Fujiwara K, Nojiri S, Hagiwara S, Kusumoto S, Inoue T, Tanaka Y, Kataoka H. Suzuki T, et al. Among authors: miyaki t. Hepatol Res. 2023 Apr;53(4):289-300. doi: 10.1111/hepr.13864. Epub 2022 Dec 16. Hepatol Res. 2023. PMID: 36461885
136 results